ALLO
Allogene Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.97
−0.51%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +31.7%
- EBIT
- +29.1%
- EPS
- +39.6%
- Free cash flow
- +40.9%
- Operating cash flow
- +40.8%
Forward estimates
Based on analyst estimates
- Revenue
- -99.7%
- EBITDA
- -23.9%
- EPS
- +9.4%
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- +27.1%
- EBIT
- +24.3%
- Net income
- +25.9%
- EPS
- +34.1%
- Free cash flow
- +25.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026